PALVELLA THERAPEUTICS, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of May [__], 2020 between Palvella Therapeutics, Inc., a Delaware corporation (the “Company”), and [__________] (“Indemnitee”).
Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. DEVELOPMENT FUNDING AND...Development Funding and Royalties Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS DEVELOPMENT FUNDING AND ROYALTIES AGREEMENT (this “Agreement”) is made and entered into effective as of December 13, 2018 (the “Effective Date”) by and between LIGAND PHARMACEUTICALS, INC., a Delaware company having a place of business at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, California 92121, U.S.A., (“Ligand”), and PALVELLA THERAPEUTICS, INC., a Delaware company having a place of business at 125 Strafford Avenue, Suite #360, Wayne, PA 19087, and its Affiliates (“Palvella”). Palvella and Ligand may be referred to herein individually as a “Party” or collectively as the “Parties.”
SEVERANCE AGREEMENTSeverance Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE PALVELLA THERAPEUTICS, INC. COMPANY 2019 EQUITY INCENTIVE PLANNon-Qualified Stock Option Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) is made between Palvella Therapeutics, Inc. Company, a Delaware corporation (the “Company”) and [________] (the “Optionee”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Pennsylvania
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on May 20, 2020 by and between Palvella Therapeutics Inc., a Delaware corporation (the “Company”), and Wesley H. Kaupinen (the “Executive”) (collectively, the “Parties”).
DEVELOPMENT FUNDING AND ROYALTIES AGREEMENTDevelopment Funding and Royalties Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT NO. 2 TO DEVELOPMENT FUNDING AND ROYALTIES AGREEMENT (this “Amendment”) is made and entered into effective as of November 29, 2023 (the “Amendment Effective Date”), by and between LIGAND PHARMACEUTICALS, INC., a Delaware company having a place of business at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, California 92121, U.S.A., (“Ligand”), and PALVELLA THERAPEUTICS, INC., a Delaware company having a place of business at 125 Strafford Avenue, Suite #360, Wayne, PA 19087, and its Affiliates (“Palvella”), and amends that certain Development Funding and Royalties Agreement, effective as of December 13, 2018 (the “Effective Date”) as amended effective as of May 22, 2020, by and between Ligand and Palvella (the “Agreement”). Palvella and Ligand may be referred to herein individually as a “Party” or collectively as the “Parties.”
INCENTIVE STOCK OPTION AGREEMENT UNDER THE PALVELLA THERAPEUTICS, INC. COMPANY 2019 EQUITY INCENTIVE PLANIncentive Stock Option Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
THIS INCENTIVE STOCK OPTION AGREEMENT (this “Agreement”) is made between Palvella Therapeutics, Inc. Company, a Delaware corporation (the “Company”) and [________] (the “Optionee”).
Palvella Therapeutics, Inc. Convertible Note Purchase AgreementConvertible Note Purchase Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations • Delaware
This Convertible Note Purchase Agreement (this “Agreement”) is made as of June [•], 2024 (the “Effective Date”) by and among Palvella Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchasers listed on Schedule I attached hereto (each a “Purchaser” and, collectively, the “Purchasers”). The Company and the Purchasers are sometimes hereinafter individually referred to herein individually as a “party” and collectively as the “parties.”
FIRST AMENDMENT TO LEASELease Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS AMENDMENT is made as of September 30, 2020, by and between The Strafford Office Buildings, having an office at 200 Eagle Road, Suite 118, Wayne, PA 19087 (hereinafter called Landlord), and Palvella Therapeutics LLC, a Delaware limited liability company (hereinafter called Tenant) having an address at 125 Strafford Avenue, Suite 360, Wayne, PA 19087.
OFFICE BUILDING LEASE STRAFFORD OFFICE BUILDINGS, WAYNE, PENNSYLVANIAOffice Building Lease • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations
Landlord: The Strafford Office Buildings a Pennsylvania General Partnership Notice Addresses: 200 Eagle Road, #118 Wayne, Pennsylvania 19087-3178 Tenant: Palvella Therapeutics LLC, a Delaware limited liability company Notice Addresses: 125 Strafford Avenue, #360 Wayne, PA 19087
FIRST AMENDMENT TO DEVELOPMENT FUNDING AND ROYALTIES AGREEMENTDevelopment Funding and Royalties Agreement • August 9th, 2024 • Pieris Pharmaceuticals, Inc. • Pharmaceutical preparations
This First Amendment to Development Funding and Royalties Agreement (this “Amendment”) is made effective as of May 22, 2020 (the “Amendment Effective Date”) by and between Ligand Pharmaceuticals Incorporated, a Delaware corporation (the “Ligand”), and Palvella Therapeutics, Inc., a Delaware corporation (“Palvella” and, together with Ligand, the “Parties” and each individually a “Party”).
